Insmed (INSM) Price & Analysis

Compare

912 Followers

INSM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$60.40 - $113.10

Previous CloseN/A

Volume462.72K

Average Volume (3M)3.65M

Market Cap

$21.13B

Enterprise Value$13.91B

Total Cash (Recent Filing)$1.20B

Total Debt (Recent Filing)$1.14B

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Oct 23, 2025

EPS Estimate

-1.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.70

Shares Outstanding189,951,420

10 Day Avg. Volume2,614,008

30 Day Avg. Volume3,653,399

Financial Highlights & Ratios

PEG Ratio-2.88

Price to Book (P/B)39.69

Price to Sales (P/S)31.14

P/FCF Ratio-16.05

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue36.50

Enterprise Value/Gross Profit47.92

Enterprise Value/Ebitda-14.95

Forecast

1Y Price Target

$118.02

Price Target Upside7.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Market PotentialCRSsNP represents a large patient population, with potential peak sales reaching around $3 billion, indicating a significant market potential.

Regulatory ProgressAll FDA communications for brensocatib have been on time, with approval expected without delays.

Revenue PerformanceArikayce revenue of $107M beat consensus estimates, indicating robust growth.

Bears Say

Investor SkepticismThere is limited preclinical or clinical evidence directly linking NSP reduction to symptom relief in CRSsNP patients, contributing to some investor skepticism.

Limited EvidenceThe strategy of NSP inhibition is seen as attractive due to low investor expectations and a significant market opportunity.

Insmed News

Insmed price target raised to $120 from $108 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $120 from $108 and...

6h ago

INSM

Insmed price target raised to $133 from $124 at UBS

UBS raised the firm’s price target on Insmed (INSM) to $133 from $124 and keeps a Buy rating...

7h ago

INSM

Insmed reports Q2 EPS ($1.70), consensus ($1.31)

Reports Q2 revenue $107.4M, consensus $104.31M. “Q2 of 2025 heralded another important milestone for patients and Insmed (INSM),...

1d ago

INSM

Insmed backs 2025 global Arikayce revenues view $405M-$425M

Consensus for 2025 revenue is $466.61M. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

1d ago

INSM

Insmed price target raised to $130 from $119 at Wells Fargo

Wells Fargo analyst Tiago Fauth raised the firm’s price target on Insmed (INSM) to $130 from $119 and...

17d ago

INSM

Insmed price target raised to $108 from $102 at Morgan Stanley

Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Insmed (INSM) to $108 from $102 and...

23d ago

INSM

Insmed Positioned for Growth: Buy Rating Backed by Brensocatib Launch and Strong Pipeline

Analyst Maxwell Skor from Morgan Stanley maintained a Buy rating on Insmed and increased the price target to...

7h ago

INSM

Insmed Reports Strong Growth and Strategic Advances

Insmed ( ($INSM) ) has released its Q2 earnings. Here is a breakdown of the information Insmed presented...

13h ago

INSM

Insmed’s Strong Financial Performance and Promising Drug Pipeline Drive Buy Rating

Insmed, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD...

24h ago

INSM

INSM Upcoming Earnings Report: What to Expect?

Insmed (INSM) is scheduled to report 2nd quarter earnings on 08/07/2025, before the market opens. Regarding Q2 estimates,...

3d ago

INSM

Insmed’s Promising Outlook: Buy Rating Backed by Brenso Launch and Market Potential

Tiago Fauth, an analyst from Wells Fargo, maintained the Buy rating on Insmed. The associated price target was...

17d ago

INSM

Insmed price target raised to $111 from $90 at JPMorgan

JPMorgan raised the firm’s price target on Insmed (INSM) to $111 from $90 and keeps an Overweight rating...

1M ago

INSM

Insmed, Deutsche Bank, Booking, Uber, DoorDash: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($INSM) ), ( ($DB) ), ( ($BKNG) ), ( ($UBER)...

2M ago

BKNG

Insmed Announces $650 Million Public Stock Offering

Insmed ( ($INSM) ) has shared an update. On June 11, 2025, Insmed announced the commencement and pricing...

2M ago

INSM

INSM FAQ

What was Insmed’s price range in the past 12 months?

Insmed lowest stock price was $60.40 and its highest was $113.10 in the past 12 months.

What is Insmed’s market cap?

Insmed’s market cap is $21.13B.

When is Insmed’s upcoming earnings report date?

Insmed’s upcoming earnings report date is Oct 23, 2025 which is in 76 days.

How were Insmed’s earnings last quarter?

Insmed released its earnings results on Aug 07, 2025. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.293 by -$0.407.

Is Insmed overvalued?

According to Wall Street analysts Insmed’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Insmed pay dividends?

Insmed does not currently pay dividends.

What is Insmed’s EPS estimate?

Insmed’s EPS estimate is -1.34.

How many shares outstanding does Insmed have?

Insmed has 189,951,420 shares outstanding.

What happened to Insmed’s price movement after its last earnings report?

Insmed reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.293. Following the earnings report the stock price went down -1.762%.

Which hedge fund is a major shareholder of Insmed?

Currently, no hedge funds are holding shares in INSM

Insmed Stock Smart Score

Outperform

Fundamentals

Return on Equity

-160.54%

Trailing 12-Months

Asset Growth

37.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed (INSM) Earnings & Revenues

Historic Earnings Reports

INSM Company Deck

INSM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance, significant progress in clinical programs, and promising regulatory advancements. However, challenges remain in navigating regulatory processes and potential tariff impacts. Overall, the positive aspects, particularly the revenue growth and clinical milestones, outweigh the lowlights.View all INSM earnings summaries

INSM Stock 12 Month Forecast

Average Price Target

$118.02

▲(7.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","136":"$136","84.25":"$84.3","101.5":"$101.5","118.75":"$118.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118.02,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$118.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$101.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,84.25,101.5,118.75,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,110.71384615384615,112.7376923076923,114.76153846153846,116.78538461538461,118.80923076923077,120.83307692307692,122.85692307692307,124.88076923076923,126.90461538461538,128.92846153846153,130.9523076923077,132.97615384615384,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,109.4076923076923,110.12538461538462,110.84307692307692,111.56076923076922,112.27846153846154,112.99615384615385,113.71384615384615,114.43153846153845,115.14923076923077,115.86692307692307,116.58461538461538,117.30230769230769,{"y":118.02,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,108.69,108.09846153846154,107.50692307692307,106.91538461538461,106.32384615384615,105.73230769230769,105.14076923076922,104.54923076923077,103.95769230769231,103.36615384615385,102.77461538461539,102.18307692307692,101.59153846153846,{"y":101,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >